- Our Products & Expertise
- About Baxter
- Corporate Responsibility
- Contact & Support
It looks like your browser is outdated. For the best experience, please consider updating to the latest version or switching to another browser (Firefox, Chrome, Safari).
As we prepare for the next phase of our journey, we are committed to working on your behalf to build long-term shareholder value in pursuit of our mission.
2015 was a pivotal year for Baxter: In July we executed the spinoff of our BioScience business. The corporate separation created value for investors and resulted in a Baxter portfolio focused solely on the Hospital Products and Renal technologies central to our core identity. Today we are collaborating around the world to shape a leaner, more efficient company, positioned to deliver on our mission and succeed on behalf of all our stakeholders well into the future.View our latest Annual Report
|Data provided by Nasdaq. Minimum 15 minutes delayed.|
Baxter Announces Health Canada Approval of AMIA Automated Peritoneal Dialysis System with SHARESOURCE Connectivity Platform
Baxter Recognized as One of the Most Community-Minded Companies in the United States by Points of Light
Analysts, portfolio managers, and current and prospective shareholders seeking additional investor information can contact Clare Trachtman at +1 (224) 948-3085.
Retail shareholder inquires may directed to Baxter Investor Relations at Global_CORP_Investor_Relations@baxter.com.Sign up for email alerts